Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

Martin C. Mueller, MD, Philipp Erben, MD, Thomas Ernst, MD, Michelle Giehl, PhD, Thomas Schenk, MD, Jana Hoffmann, Stephanie Lauber, MD, Jens Kruth, MD, Benjamin Hanfstein, MD, Eric Bleickardt, MD, Claude Nicaise, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2007) 110 (11): 319.

https://doi.org/10.1182/blood.V110.11.319.319

Published: 2007

Journal Articles

A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis.

Andreas Hochhaus, MD, Oliver G. Ottmann, MD, STephanie Lauber, MD, Timothy Hughes, MD, Gregor Verhoef, MD, Anthony P. Schwarer, MD, Alois Gratwohl, MD, Teresa Rafferty, RN, Debra Resta, RN, Norbert Gattermann, MD

Blood (2006) 108 (11): 2703.

https://doi.org/10.1182/blood.V108.11.2703.2703

Published: 2006

Journal Articles

Sensitive Detection of c-kit Point Mutations by D-HPLC in Peripheral Blood and Bone Marrow Samples from Patients with Systemic Mastocytosis.

Stephanie Lauber, MD, Martin C. Mueller, MD, Philipp Erben, MD, Thomas Schenk, MD, Jens Kruth, MD, Georgia Metzgeroth, MD, Thomas Ernst, MD, Peter Paschka, MD, Rudiger Hehlmann, MD, Andreas Reiter, MD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 3624.

https://doi.org/10.1182/blood.V108.11.3624.3624

Published: 2006

Journal Articles

Diagnosis and Monitoring of Residual Disease by Quantitative RT-PCR in Eosinophilia-Associated Myeloproliferative Disorders with Rearrangements of PDGFRA and PDGFRB.

Philipp Erben, MD, Martin C. Mueller, MD, Georgia Metzgeroth, MD, Helena Popp, Christoph Walz, MD, Thomas Schenk, MD, Stephanie Lauber, MD, Jens Kruth, MD, Nicholas C.P. Cross, PhD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD, Andreas Reiter, MD

Blood (2006) 108 (11): 2690.

https://doi.org/10.1182/blood.V108.11.2690.2690

Published: 2006

Journal Articles

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Martin C. Müller, MD, Philipp Erben, MD, Thomas Schenk, MD, Stephanie Lauber, MD, Jens Kruth, MD, Jana Hoffmann, Thomas Ernst, MD, Tanja Lahaye, MD, Georgia Metzgeroth, MD, Michael Acevedo, PhD, Claude Nicaise, MD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 748.

https://doi.org/10.1182/blood.V108.11.748.748

Published: 2006

Journal Articles

Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories.

Martin C. Mueller, MD, Philipp Erben, MD, Giuseppe Saglio, MD, Enrico Gottardi, PhD, Thomas Schenk, MD, Thomas Ernst, MD, Stephanie Lauber, MD, Michael Emig, MD, Ruediger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2005) 106 (11): 1991.

https://doi.org/10.1182/blood.V106.11.1991.1991

Published: 2005

NARROW

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis.

Sensitive Detection of c-kit Point Mutations by D-HPLC in Peripheral Blood and Bone Marrow Samples from Patients with Systemic Mastocytosis.

Diagnosis and Monitoring of Residual Disease by Quantitative RT-PCR in Eosinophilia-Associated Myeloproliferative Disorders with Rearrangements of PDGFRA and PDGFRB.

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories.

Email alerts

ASH Publications

American Society of Hematology

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis.

Sensitive Detection of c-kit Point Mutations by D-HPLC in Peripheral Blood and Bone Marrow Samples from Patients with Systemic Mastocytosis.

Diagnosis and Monitoring of Residual Disease by Quantitative RT-PCR in Eosinophilia-Associated Myeloproliferative Disorders with Rearrangements of PDGFRA and PDGFRB.

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only